艾美疫苗今年三款重磅迭代升級疫苗申報上市,國際市場佈局業已展開
艾美疫苗(6660.HK)今日公佈2023財年業績報吿,期內研發費用超6.36億元,同比增長27.2%,今年3款重磅迭代升級疫苗申報上市,7款申報臨牀。截至2023年底,艾美取得了14個臨牀批件,開展了21項臨牀試驗,5個處於III期臨牀收尾階段。目前,13價肺炎結合疫苗、無血清迭代狂犬疫苗、23價肺炎多糖疫苗等3款重磅迭代升級疫苗,今年完成上市申報,有望儘快為公司業績帶來大幅增長。公司重磅迭代升級產品四價MDCK細胞流感疫苗、20價肺炎結合疫苗、新型工藝高效價人二倍體狂犬疫苗等多款產品也已提交臨牀試驗預申請。另據業績公吿,艾美疫苗在海外上市許可、產品研發、生產等方面均已做好全方位準備,目前已在東南亞、非洲、南美、中東等地區開始已上市產品的註冊工作。公司狂犬疫苗已獲得巴基斯坦等多國的註冊許可。正努力推動國際市場緊缺的品種肺炎結合疫苗、呼吸道合胞病毒疫苗、帶狀皰疹疫苗等,在國內外的上市註冊與銷售。公司已上市的甲肝疫苗、乙肝疫苗和狂犬疫苗都是國際市場青睞的品種。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.